ライフサイエンスコーパス: functional assessment

1 the Clinical Dementia Rating Scale (a global functional assessment).

2 nt EAP, cognitive, and thorough clinical and functional assessment.

3 us MAF2 gene and its paralogues, confounding functional assessment.

4 quired regarding cell seeding strategies and functional assessment.

5 ion of advanced stage fibrosis and providing functional assessment.

6 ing with opportunities for both anatomic and functional assessment.

7 cestry, followed by extensive biological and functional assessment.

8 rentially expressed genes for validation and functional assessment.

9 in dysfunction by particle size, number, and functional assessment.

10 entiation, based on both marker analysis and functional assessment.

11 e and post TAC end points for structural and functional assessment.

12 mia; and (iii) combine histopathological and functional assessments.

13 rms to compare trajectories of GSL, QBA, and functional assessments.

14 enrolled subjects had baseline cognitive and functional assessments.

15 evaluated using diagnostic, symptomatic, and functional assessments.

16 2 years on 6 muscles unilaterally along with functional assessments.

17 burden and self-reported and examiner-rated functional assessments.

18 events, which typically are distinguished by functional assessments.

19 interviews with informants and patients, and functional assessments.

20 Functional assessments (6-minute walk distance, 4-meter

21 Clinical and functional assessments along with transcranial magnetic

22 Clinical and functional assessment, along with motor-nerve excitabili

23 g daily donepezil on the Alzheimer's Disease Functional Assessment and Change Scale.

24 stoperative cine MRI for global and regional functional assessment and delayed-enhancement MRI for as

25 223 respondents had a baseline cognitive and functional assessment and had linked Medicare claims; 51

26 e resolution to select a specific region for functional assessment and interferometric phase sensitiv

27 rmation enabled experimental recapitulation, functional assessment and mechanistic elucidation of the

28 ocardial recovery and should be targeted for functional assessment and optimization.

29 adequate perioperative risk stratification, functional assessment, and oncologic prognostication, el

30 Here we use synthetic chemistry, functional assessment, and structure-based analysis to e

31 iagnostic findings, including morphological, functional assessment, and treatment of patients with MB

32 ategorical clinical ratings and quantitative functional assessments, and a number of other important

33 These parameters may be useful alongside functional assessments as the outcome measurements for f

34 These studies relied on the functional assessment, based on clinical score, of condi

35 often involve an ordinal scale of subjective functional assessments but the optimal way to quantify r

36 results are apparently discordant with renal functional assessment by allowing identification of pati

37 ded radiographic damage (the Larsen method), functional assessment by the Health Assessment Questionn

38 nocytochemical staining in kidney slices and functional assessments (Ca(2+) imaging) in isolated, spl

39 integrity and RA is an optimal parameter for functional assessment compared with axial or radial diff

40 rain natriuretic peptide and Troponin T, and functional assessment comprising the 6-minute walk test

41 rthermore, the combination of anatomical and functional assessments configuring a hybrid approach may

42 Functional assessment confirmed at least two compounds a

43 Follow-on pathological and functional assessment confirmed cyclin D1 and SPP1 as ke

44 included pain (visual analogue scale score), functional assessment (Constant-Murley score), and resol

45 Early functional assessment (day 1 after acute myocardial infa

46 Furthermore, a combined anatomical and functional assessment does not add incremental diagnosti

47 cer patients with fatigue as measured by the Functional Assessment for Chronic Illness Therapy-Fatigu

48 as measured using the 0 to 10 scale, and the Functional Assessment for Chronic Illness Therapy-Fatigu

49 to GSL, and both appear more sensitive than functional assessments for detecting muscle deterioratio

50 In silico functional assessment further supported this relationshi

51 or the diagnosis of cirrhosis, and providing functional assessment in advanced stage disease.

52 hearing assessment and treatment as part of functional assessment in an interdisciplinary, team-base

53 ue to provide improved means of anatomic and functional assessment in children and adults with congen

54 In vitro functional assessment in HEK293 cells of the impact of t

55 l Status Scale is a promising instrument for functional assessment in outpatients with schizophrenia.

56 The primary functional assessment in this study was the 6-Minute Wal

57 a, alongside any role in tumorigenesis using functional assessments in mouse and human models.

58 Functional assessments included the Barthel Index, the L

59 Conclusion: Murine LV functional assessment is feasible with high spatial and

60 Functional assessment is still required in lesions of mo

61 structive coronary artery disease (CAD), but functional assessment is warranted in the presence of a

62 LFDR complements functional assessments like gene set enrichment analysis

63 A multimodal functional assessment may be more effective in detecting

64 ing culture systems, preclinical models, and functional assessment, may improve clinical application

65 hours active per day and changes in standard functional assessments (New York Heart Association, qual

66 measurement of basal p53 protein levels and functional assessment of (a) transcriptional activity of

67 Functional assessment of 16 OATP-C alleles in vitro reve

68 e entire coronary tree, may be ideal for TAG functional assessment of a coronary arterial stenosis.

69 in addition to biomarker-based segregation, functional assessment of a patient's tumor before treatm

70 -chip technology with human patch-clamp in a functional assessment of a previously undescribed Nav1.7

71 Assessment Scale, and quality of life by the Functional Assessment of Anorexia/Cachexia Therapy (FAAC

72 The Functional Assessment of Anorexia/Cachexia Therapy quest

73 In contrast, 4-week Functional Assessment of Anorexia/Cachexia Therapy score

74 lt to measure in human tumor samples, making functional assessment of autophagy problematic in a clin

75 Functional assessment of bile salt excretion was determi

76 tive coronary angiography does not provide a functional assessment of CAD as available from pressure

77 11-item neurotoxicity (NTX) component of the Functional Assessment of Cancer Therapy (FACT) -Taxane s

78 ctive of treatment arm) had a mean change in Functional Assessment of Cancer Therapy (FACT) fatigue s

79 ful decline in quality of life (QOL) via the Functional Assessment of Cancer Therapy (FACT)-Lung Canc

80 significant improvement was shown in median Functional Assessment of Cancer Therapy (FACT)-Prostate

81 (EuroQol-5D), and cancer-specific outcomes (Functional Assessment of Cancer Therapy and Social Diffi

82 The Functional Assessment of Cancer Therapy and Uniscale ins

83 utcome was self-reported cognitive function (Functional Assessment of Cancer Therapy Cognitive Functi

84 Criteria, and patient-reported QOL using the Functional Assessment of Cancer Therapy for Patients wit

85 Events and peripheral neuropathy by modified Functional Assessment of Cancer Therapy questionnaire an

86 mptom Assessment Scale) and quality of life (Functional Assessment of Cancer Therapy Scale).

87 study by patient-reported symptoms using the Functional Assessment of Cancer Therapy Scale/Gynecologi

88 usion [8 weeks only]), FACT-B, FACT-ES, (and Functional Assessment of Cancer Therapy subscales of phy

89 ompleted the colorectal cancer module of the Functional Assessment of Cancer Therapy survey (FACT-C).

90 Changes in QOL (eg, Functional Assessment of Cancer Therapy) from before ran

91 l Outcomes Study SF-36) and cancer-specific (Functional Assessment of Cancer Therapy) scales.

92 d patient-reported outcomes according to the Functional Assessment of Cancer Therapy-Anemia (FACT-An)

93 ts from clinical trials, we administered the Functional Assessment of Cancer Therapy-Anemia (FACT-An)

94 d anemia and fatigue were evaluated with the Functional Assessment of Cancer Therapy-Anemia and Funct

95 lity of life) and the anemia subscale of the Functional Assessment of Cancer Therapy-Anemia questionn

96 Patients completed cancer-specific QOL (Functional Assessment of Cancer Therapy-Biologic Respons

97 nt Health Questionnaire, PTSD checklist, and Functional Assessment of Cancer Therapy-Bone Marrow Tran

98 tem Short-Form Health Survey (SF-36) and the Functional Assessment of Cancer Therapy-Bone Marrow Tran

99 lity of life after transplantation using the Functional Assessment of Cancer Therapy-Bone Marrow Tran

100 Main Outcomes and Measures: Functional Assessment of Cancer Therapy-Bone Marrow Tran

101 Quality of life, as assessed by using Functional Assessment of Cancer Therapy-Bone Pain (FACT-

102 t-reported quality of life assessed with the Functional Assessment of Cancer Therapy-Brain (FACT-Br)

103 The Functional Assessment of Cancer Therapy-Breast (FACT-B)

104 Patients completed the Functional Assessment of Cancer Therapy-Breast (FACT-B)

105 Scale (MSAS)-Global Distress Index (GDI) and Functional Assessment of Cancer Therapy-Breast (FACT-B)

106 file of Mood States (POMS; primary outcome), Functional Assessment of Cancer Therapy-Breast (FACT-B),

107 st published report on the validation of the Functional Assessment of Cancer Therapy-Breast (FACT-B),

108 l QOL; health-related QOL as measured by the Functional Assessment of Cancer Therapy-Breast Cancer (F

109 apy relative to usual care were recorded for Functional Assessment of Cancer Therapy-Breast, social/f

110 uality-of-life endpoint was the score on the Functional Assessment of Cancer Therapy-Cervix Trial Out

111 age-matched noncancer controls completed the Functional Assessment of Cancer Therapy-Cognitive Functi

112 We measured HRQL with the Functional Assessment of Cancer Therapy-Colorectal (FACT

113 QoL was assessed with the Functional Assessment of Cancer Therapy-Colorectal (FACT

114 at baseline and 1 year postoperatively: the Functional Assessment of Cancer Therapy-Colorectal (FACT

115 with LRRC using the Brief Pain Inventory and Functional Assessment of Cancer Therapy-Colorectal quest

116 nt decrease in levels of endocrine symptoms (Functional Assessment of Cancer Therapy-Endocrine Sympto

117 ssessment of Cancer Therapy-Breast (FACT-B), Functional Assessment of Cancer Therapy-Endocrine Sympto

118 Patients also completed quality-of-life (Functional Assessment of Cancer Therapy-Endocrine Sympto

119 scopy patients reported significantly higher Functional Assessment of Cancer Therapy-General (FACT-G)

120 QOL measures included the Functional Assessment of Cancer Therapy-General (FACT-G)

121 te QOL assessments at four time points using Functional Assessment of Cancer Therapy-General (FACT-G)

122 ents of four validated scales were used--the Functional Assessment of Cancer Therapy-General (FACT-G)

123 HRQOL was assessed with the Functional Assessment of Cancer Therapy-General (FACT-G)

124 Patient-reported measures included the Functional Assessment of Cancer Therapy-General (FACT-G)

125 significant mean difference of 9.8 units in Functional Assessment of Cancer Therapy-General (primary

126 he extent of disease, quality-of-life score (Functional Assessment of Cancer Therapy-General [FACT-G]

127 The Functional Assessment of Cancer Therapy-General instrume

128 ancer Quality of Life Questionnaire C-30 and Functional Assessment of Cancer Therapy-General instrume

129 quality of life as measured by the change in Functional Assessment of Cancer Therapy-General Measure

130 d the Hospital Anxiety and Depression Scale, Functional Assessment of Cancer Therapy-General quality-

131 were patient HRQL over time, measured by the Functional Assessment of Cancer Therapy-General question

132 from baseline to week 12, per scoring by the Functional Assessment of Cancer Therapy-General scale.

133 lysis of variance method was used to compare Functional Assessment of Cancer Therapy-General scores o

134 ns Questionnaire), coping (Brief COPE), QOL (Functional Assessment of Cancer Therapy-General), and mo

135 Participants completed assessments of QOL (Functional Assessment of Cancer Therapy-General), depres

136 gnificant improvement in QOL as shown by the Functional Assessment of Cancer Therapy-General, compare

137 QOL improvement rates (Functional Assessment of Cancer Therapy-Head & Neck tota

138 reatment using standardized measures of QOL (Functional Assessment of Cancer Therapy-Head and Neck) a

139 Standardized measures of QOL (Functional Assessment of Cancer Therapy-Head and Neck),

140 Quality of life (QOL) was assessed using Functional Assessment of Cancer Therapy-Head and Neck.

141 onal Assessment of Cancer Therapy-Anemia and Functional Assessment of Cancer Therapy-Head and Neck.

142 The Brief Pain Inventory (BPI), Functional Assessment of Cancer Therapy-Hepatobiliary (F

143 he development and initial validation of the Functional Assessment of Cancer Therapy-Hepatobiliary (F

144 Measurement of quality of life using the Functional Assessment of Cancer Therapy-Hepatobiliary qu

145 nterim analysis, HRQoL was assessed with the Functional Assessment of Cancer Therapy-Kidney Symptom I

146 nificantly higher overall mean scores in the Functional Assessment of Cancer Therapy-Kidney Symptom I

147 ate by the Lung Cancer Subscale (LCS) of the Functional Assessment of Cancer Therapy-Lung (FACT-L) qu

148 baseline and at 12 weeks with the use of the Functional Assessment of Cancer Therapy-Lung (FACT-L) sc

149 dictive ability of the five subscales of the Functional Assessment of Cancer Therapy-Lung (physical,

150 Changes in QOL over time (measured by the Functional Assessment of Cancer Therapy-Lung questionnai

151 QoL-5D (EQ-5D), and Melanoma Subscale of the Functional Assessment of Cancer Therapy-Melanoma (FACT-M

152 varian Cancer Module 28 (EORTC QLQ-OV28) and Functional Assessment of Cancer Therapy-Ovarian Cancer s

153 lth-related quality of life (HRQoL) with the Functional Assessment of Cancer Therapy-Prostate (FACT-P

154 The Functional Assessment of Cancer Therapy-Prostate (FACT-P

155 Serial measurements in 24 patients using the Functional Assessment of Cancer Therapy-Prostate (FACT-P

156 d at baseline and during treatment using the Functional Assessment of Cancer Therapy-Prostate (FACT-P

157 (UCLA-PCI), including Short Form (SF)-36 and Functional Assessment of Cancer Therapy-Prostate (FACT-P

158 a prostate cancer-specific checklist or the Functional Assessment of Cancer Therapy-Prostate questio

159 ant deterioration in both arms over time for Functional Assessment of Cancer Therapy-Prostate total s

160 quality of life (QoL), assessed by using the Functional Assessment of Cancer Therapy-Prostate.

161 The Functional Assessment of Cancer Therapy-Trial Outcome In

162 The Functional Assessment of Cancer Therapy/Gynecologic Onco

163 t baseline and after every two cycles by the Functional Assessment of Cancer Therapy/Gynecologic Onco

164 The questionnaire, referred to as the Functional Assessment of Cancer Therapy/Gynecologic Onco

165 IPN-sx were evaluated with the self-reported Functional Assessment of Cancer Therapy/Gynecologic Onco

166 This was confirmed by the results of the Functional Assessment of Cancer Treatment questionnaire.

167 ration in quality of life as measured by the Functional Assessment Of Cancer Treatment--Breast were c

168 er" alleles and underscore the importance of functional assessment of candidate disease alleles.

169 iding an efficient tool for the recovery and functional assessment of candidate genes.

170 mmalian cells, and suggest an avenue for the functional assessment of chromatin-associated proteins.

171 Fatigue was measured using the Functional Assessment of Chronic Illness Therapy (FACIT)

172 The primary outcome was change in Functional Assessment of Chronic Illness Therapy (FACIT)

173 s (FACT-Trial Outcome Index [TOI]), fatigue (Functional Assessment of Chronic Illness Therapy [FACIT]

174 Short Form-36], and cancer-related fatigue [Functional Assessment of Chronic Illness Therapy Fatigue

175 es, the Short Form 36 vitality subscale, the Functional Assessment of Chronic Illness Therapy Fatigue

176 Secondary and other endpoints included the functional assessment of chronic illness therapy fatigue

177 Quality of life was measured by the Functional Assessment of Chronic Illness Therapy for Pal

178 of placebo (PL) on CRF as measured using the Functional Assessment of Chronic Illness Therapy-Fatigue

179 ESC), Unified Myoclonus Rating Scale (UMRS), Functional Assessment of Chronic Illness Therapy-Fatigue

180 outcomes, including fatigue measured by the Functional Assessment of Chronic Illness Therapy-Fatigue

181 Additional end points included scores on the Functional Assessment of Chronic Illness Therapy-Fatigue

182 For this quantitative study, we selected the Functional Assessment of Chronic Illness Therapy-Fatigue

183 with respect to vitality, as assessed by the Functional Assessment of Chronic Illness Therapy-Fatigue

184 (36) Health Survey version 2 (SF-36v2), the Functional Assessment of Chronic Illness Therapy-Fatigue

185 36, Chronic Liver Disease Questionnaire-HCV, Functional Assessment of Chronic Illness Therapy-Fatigue

186 r PRO questionnaires (Short Form-36 [SF-36], Functional Assessment of Chronic Illness Therapy-Fatigue

187 estimates of QOL translated to units of the Functional Assessment of Chronic Illness Therapy-palliat

188 Questionnaire (KCCQ) overall summary and the Functional Assessment of Chronic Illness Therapy-Palliat

189 s of standardised instruments, including the functional assessment of chronic illness therapy-spiritu

190 The primary end point was change in the Functional Assessment of Chronic Illness-Fatigue (FACIT-

191 (CREST-seq), for the unbiased discovery and functional assessment of cis-regulatory sequences in the

192 drug screening, diagnostic applications and functional assessment of complex membrane proteins like

193 try, fluorescent dye diffusion technique for functional assessment of connexin43, telemetry monitorin

194 s the established reference standard for the functional assessment of coronary artery disease (CAD) (

195 entially be used for improved anatomical and functional assessment of coronary artery disease at a re

196 A provide comparable diagnostic accuracy for functional assessment of coronary artery stenosis.

197 may provide the best diagnostic accuracy for functional assessment of coronary artery stenosis.

198 immunohistochemistry staining for Cx43, and functional assessment of Cx43 with fluorescent dye diffu

199 fects of genetic variation and may allow for functional assessment of disease-associated loci.

200 oietic progenitor cells, a comprehensive and functional assessment of entirely in vitro generated CD8

201 Because this GTI provides a more functional assessment of gas trapping and airway disease

202 peptide YY plasma concentration with bedside functional assessment of gastric emptying.

203 Functional assessment of gated individual dermal microve

204 The functional assessment of genes with increased expression

205 s, SAS mutational libraries can expedite the functional assessment of genetic variation.

206 As a functional assessment of GSK-3beta phosphorylation, TLR4

207 Functional assessment of HIV-specific T cells by multipa

208 are essential and instructive modalities for functional assessment of human genetic variations.

209 Here we have presented the first functional assessment of IDE in AD families showing the

210 range detectors of unknown threat agents and functional assessment of identified agents.

211 This study highlights that functional assessment of identified nucleotide changes i

212 Functional assessment of IL-4 expression was also perfor

213 Functional assessment of iMGLs reveals that they secrete

214 es and ranked the genes and loci for further functional assessment of known cancer risk loci.

215 Functional assessment of miR-31 activity revealed its ab

216 of high-throughput, unbiased approaches for functional assessment of most noncoding variants has bot

217 findings of computed tomography, based on a functional assessment of myocardial blood flow, thereby

218 Functional assessment of NCC by using thiazide-sensitive

219 might serve as a useful imaging tool for the functional assessment of neuroblastic tumors.

220 Identification and functional assessment of new Nav1.9 mutations will help

221 Functional assessment of nonsynonymous variant supported

222 Functional assessment of recombinant KGF in a proliferat

223 ing is a promising noninvasive technique for functional assessment of renal allografts.

224 Functional assessment of skinned myocytes, however, reve

225 Functional assessment of specific sequences that contrib

226 Functional assessment of structural analogs of the proto

227 ment and find monetary rewards, allowing the functional assessment of the brain systems for spatial l

228 or new and improved model systems that allow functional assessment of the corresponding gene products

229 Compromised QOL provides a functional assessment of the effects of chronic GVHD, an

230 The strategy should allow the functional assessment of the expression of dominantly ac

231 ESTs are in the Gateway vector to facilitate functional assessment of the genes.

232 ing can provide both a detailed anatomic and functional assessment of the pediatric genitourinary tra

233 for rapid growth and full Hsp90 activity, a functional assessment of the PPIase domain could be perf

234 and adult tissues as a first step toward the functional assessment of the receptor.

235 superior to UW alone in both morphologic and functional assessment of the transplanted pancreas.

236 the role of urodynamics, particularly in the functional assessment of the urethra, it is clear that t

237 Functional assessment of these antibodies yielded an inh

238 sferase-mediated dUTP nick end labeling, and functional assessment of ventricular performance.

239 e activity may be useful as a marker for the functional assessment of zinc status in humans.

240 luding use of sensitive analytical tools for functional assessments of biofilm formation, riboflavin

241 Functional assessments of CD8(+) cells sorted into disti

242 , we combined global repertoire analyses and functional assessments of isolated T cell receptors (TCR

243 matically segmented from K1 images to derive functional assessments of LV mass (mLV) and wall thickne

244 Structural, biochemical, and functional assessments of pulmonary vessels, including i

245 These data suggest that functional assessments of single Abs may inaccurately pr

246 tion of a membrane protein, which allows for functional assessments of various peptide regions.

247 y interpreted in the context of an extensive functional assessment, or family segregation analysis of

248 aracterized using the SHIRPA behavioural and functional assessment protocol.

249 Decline in scores on the Functional Assessment Questionnaire and Trail Making Tes

250 n an everyday functional activities measure (Functional Assessment Questionnaire) was considerably la

251 cluding age at JRA onset, Juvenile Arthritis Functional Assessment Report (JAFAR) score, triceps skin

252 ine kinase level, and the Juvenile Arthritis Functional Assessment Report score.

253 In vitro functional assessment revealed that the A516C and A404T

254 as assessed through the Child and Adolescent Functional Assessment Scale (CAFAS).

255 ew of all available information, including a functional assessment screen.

256 Functional assessment showed durable improvement in vest

257 A functional assessment showed good agreement with standar

258 Functional assessment showed reduced surface expression

259 Functional assessment shows no significant loss of perip

260 the atrophy of the cerebellar cortex and the Functional Assessment Staging (FAST) measure of the clin

261 was compared with the cut point of 7c on the Functional Assessment Staging (FAST) scale.

262 proANP levels performed with replication and functional assessment that identified genetic variants i

263 ts in patients, starting with phenotypic and functional assessments that lead to analysis of candidat

264 As an initial functional assessment, the cells were compared to non-tr

265 y based treatments, specifically the rise of functional assessment; the recognition that pharmacother

266 ly distant species for genetic screening and functional assessment to identify modifiers of neurodege

267 We hypothesized that combining functional assessment to perfusion enhances the ability

268 be complemented by additional structural and functional assessments to minimize the risk of false rea

269 was developed from 2 existing observational functional assessment tools to assess muscle function in

270 Functional assessments using Langendorff preparations an

271 Functional assessment was performed by the use of an in

272 ell transplantation, MRI, and neurocognitive functional assessments, we demonstrate that bone marrow-

273 Cognitive and functional assessments were also performed.

274 Symptom and functional assessments were analysed at 7 days, 30 days,

275 Neuropsychological and functional assessments were carried out at study entry a

276 tructure and function, blood chemistries and functional assessments were obtained.

277 s underwent MR imaging of the affected knee, functional assessment with use of the International Knee

278 ed to a conservative strategy of noninvasive functional assessment, with angiography reserved for pat